Register now to R3i !
Your Login
Your Password
Confirm Password  
Your Email
I agree to receive
the R3i newsletter

RECENT PUBLICATIONS ON RESIDUAL RISK

2018

Dyslipidemia International Survey-China survey highlights atherogenic dyslipidaemia

In the Dyslipidemia International Survey-China survey, over 50% of patients had persistent atherogenic dyslipidaemia despite attainment of low-density lipoprotein cholesterol (LDL-C) goal on statin therapy. This report analysed data from 22,039 patients receiving statin monotherapy, enrolled at 122 hospitals in China. Atherogenic dyslipidaemia was defined as triglyceride levels ?1.7mmol/L and/or low levels of high-density lipoprotein cholesterol (men: <1.0mmol/L; women: <1.3mmol/L). Based on the US National Cholesterol Education Program Adult Treatment Panel III criteria, of 13,088 patients who attained LDL-C goals, 7,134 patients (55%) had residual atherogenic dyslipidaemia. Results were similar using the Chinese guideline for the management of dyslipidemia: 13,551 patients reached LDL-C goal, of whom 7,719 (57%) patients had atherogenic dyslipidaemia. The intensity of statin therapy did not affect the prevalence of atherogenic dyslipidaemia. These findings highlight the need for renewed awareness of atherogenic dyslipidaemia in this region.
Risk factors associated with atherogenic dyslipidemia in the presence of optimal statin therapy.

Zhao W, Zheng XL, Jiang ZN et al.